openPR Logo
Press release

Polymyositis Therapeutics Market Size in the 7MM was ~USD 114 million in 2023, is expected to grow by 2034, and estimated DelveInsight

01-09-2025 02:28 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Polymyositis Drugs Market

Polymyositis Drugs Market

DelveInsight's "Polymyositis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Discover Key Insights into the Polymyositis Market with DelveInsight's In-Depth Report @ Polymyositis Market Size- https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Polymyositis Market Report
• In December 2024:- Cabaletta Bio- Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), and immune-mediated necrotizing myopathy (IMNM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, and IMNM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Polymyositis in the 7MM were nearly 80 thousand in 2023.
• Among the European countries, Germany had the highest diagnosed prevalent cases of Polymyositis with ~9 thousand cases, followed by France, which had diagnosed prevalent population of ~7 thousand in 2023. On the other hand, Spain had the lowest prevalent population (3 thousand cases).
• Japan had nearly 12 thousand total diagnosed prevalent cases of Polymyositis in 2023, accounting for approximately 16% in 7MM.
• The DelveInsight analysis indicates that in Japan, females were more affected than males, with approximately 9 thousand female cases and 3 thousand male cases in 2023.
• The Polymyositis Companies such as Boehringer Ingelheim Pharmaceuticals, Mitsubishi Tanabe Pharma, Janssen Pharmaceutical, Kezar Life Sciences, Bristol-Myers Squibb, ONO Pharma, Horizon Therapeutics, Immunoforge, Restem, LLC., and Eli Lilly and Company, and others.
• Promising Polymyositis Therapies such as Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others.

Stay ahead in the Polymyositis Therapeutics Market with DelveInsight's Strategic Report @ Polymyositis Market Outlook- https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Polymyositis Epidemiology Segmentation in the 7MM
• Total Polymyositis Diagnosed Prevalent Cases
• Polymyositis Gender-specific Diagnosed Prevalent Cases
• Polymyositis Age-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Polymyositis epidemiology trends @ Polymyositis Prevalence- https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Polymyositis Emerging Drugs
• SAPHNELO (Anifrolumab): AstraZeneca
SAPHNELO (anifrolumab) is a first-in-class, fully human monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor, blocking the activity of type I IFN. Type I IFNs, such as IFN-alpha, IFN-beta, and IFN-kappa, are cytokines involved in regulating the inflammatory pathways implicated in SLE. The majority of adults with SLE have increased type I IFN signaling, which is associated with increased disease activity and severity.

• Dazukibart (PF-06823859): Pfizer
The drug dazukibart (PF-06823859) is being developed to treat moderate to severe dermatomyositis and Polymyositis by Pfizer along with other indications like systemic lupus erythematosus, subacute cutaneous lupus erythematosus (SCLE), and chronic cutaneous lupus erythematosus (CCLE). Neutralizing antibodies against humanized immunoglobulin and a new biological entity (NBE) make up the therapeutic candidate. It works by specifically targeting interferon beta 1 (IFNB1) and is injected intravenously and subcutaneously.

Polymyositis Market Outlook
Polymyositis is an inflammatory muscle disease that requires a multifaceted approach to treatment, primarily focusing on reducing inflammation, managing symptoms, and preventing long-term complications. The mainstay of treatment is corticosteroids, such as prednisone, which are often administered as the first line of therapy due to their potent anti-inflammatory effects. These steroids are typically prescribed in high doses initially and gradually tapered based on the patient's response. For patients who do not respond adequately to corticosteroids or who experience significant side effects, immunosuppressive agents such as methotrexate or azathioprine are commonly used. These medications help to modulate the immune system and can be used as steroid-sparing agents to reduce the dependency on corticosteroids.

Get In-Depth Knowledge on Polymyositis Market Trends and Forecasts with DelveInsight @ Polymyositis Treatment Market- https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Polymyositis Market Report
• Coverage- 7MM
• Polymyositis Companies- Boehringer Ingelheim Pharmaceuticals, Mitsubishi Tanabe Pharma, Janssen Pharmaceutical, Kezar Life Sciences, Bristol-Myers Squibb, ONO Pharma, Horizon Therapeutics, Immunoforge, Restem, LLC., and Eli Lilly and Company, and others.
• Polymyositis Therapies- Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others.
• Polymyositis Therapeutic Assessment: Polymyositis Current marketed and Polymyositis Emerging Therapies
• Polymyositis Market Dynamics: Polymyositis Market drivers and Polymyositis Market Barriers

Unlock Strategic Insights with DelveInsight's Comprehensive Polymyositis Market Report @ Polymyositis Market Drivers and Barriers- https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1 Key Insights
2 Report Introduction
3 Polymyositis Market Overview at a Glance
4 Epidemiology and Market Forecast Methodology
5 Key Events
6 Executive Summary
7 Disease Background and Overview
8 Epidemiology and Patient Population of Polymyositis
9 Patient Journey
10 Emerging Therapies
11 Polymyositis: Seven Major Market Analysis
12 KOL Views
13 SWOT Analysis
14 Unmet needs
15 Market Access and Reimbursement
16 Appendix
17 Report Methodology
18 DelveInsight Capabilities
19 Disclaimer
18 Bibliography
19 DelveInsight Capabilities
20 Disclaimer

List of the Top Selling Market Research Reports in 2025

Celiac Disease Market- https://www.delveinsight.com/report-store/celiac-disease-cd-market
Coronary Angioplasty Market- https://www.delveinsight.com/report-store/coronary-stents-market-market
CXCR Inhibitors Market- https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Overactive Bladder Syndrome Market- https://www.delveinsight.com/report-store/overactive-bladder-market
Respiratory Syncytial Virus Market- https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Percutaneous Arterial Closure Device Market- https://www.delveinsight.com/report-store/vascular-closure-devices-market
Sglt2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Short Bowel Syndrome Drug Market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical Sealant Market- https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Brucellosis Market- https://www.delveinsight.com/report-store/brucellosis-market
Pouchitis Market- https://www.delveinsight.com/report-store/pouchitis-market
Radial Artery Compression Device Market- https://www.delveinsight.com/report-store/radial-artery-compression-devices-market
Shingles Market - https://www.delveinsight.com/report-store/shingles-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
Catheter Stabilization Devices Market- https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market
Orthopedic Splints Device Market- https://www.delveinsight.com/report-store/orthopedic-splints-market
Pediatric Neuroblastoma Market- https://www.delveinsight.com/report-store/neuroblastoma-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market-insight
Gene Therapy in CNS Disorder Market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/indwelling-catheters-market
CAR-T Pipeline- https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape
NK Cell Therapy Market- https://www.delveinsight.com/blog/nk-cell-therapy-in-cancer-treatment
Transcatheter Treatment Market- https://www.delveinsight.com/report-store/transcatheter-treatment-market
Phototherapies for Psoriasis Market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Chronic Neuropathic Pain Market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Intraocular Lens Market - https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Polymyositis Therapeutics Market Size in the 7MM was ~USD 114 million in 2023, is expected to grow by 2034, and estimated DelveInsight here

News-ID: 3809399 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Polymyositis

Polymyositis Market Outlook 2025-2034: Trends, Growth, and Forecast Analysis
Polymyositis (PM) is a rare, chronic autoimmune disease that causes muscle weakness and inflammation. It affects the muscles responsible for movement, leading to significant disability and a reduction in quality of life. As the understanding of autoimmune diseases expands and new therapeutic options emerge, the polymyositis market is experiencing significant growth. This article explores the key drivers, market trends, challenges, and growth opportunities in the polymyositis market, projected to expand
Polymyositis Market Size Forecasted To Achieve $2.23 Billion By 2029 With Steady …
The Polymyositis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Polymyositis Market Size and Projected Growth Rate? The market size for polymyositis has experienced solid growth in previous years. The market is projected to rise from $1.65 billion in 2024 to $1.75 billion
Polymyositis Clinical Pipeline | 7+ Innovators Pushing the Boundaries of Treatme …
The Polymyositis market is advancing with groundbreaking research and innovative therapeutic developments. DelveInsight's 'Polymyositis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Polymyositis therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Polymyositis pipeline domain. For Polymyositis emerging drugs, the Polymyositis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product
Polymyositis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Polymyositis Pipeline Insight 2024" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Polymyositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Polymyositis Research. Learn more about our innovative pipeline
Polymyositis Treatment Market Size Research Report 2024
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Polymyositis Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in
Polymyositis Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Polymyositis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Polymyositis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Polymyositis market size from 2019 to 2032, segmented